After Hours
$
228.06
Change
+0.33 +0.14%
Volume
Volume 170,249
Mar 5, 2021, 7:52 p.m.
Quotes are delayed by 20 min
Previous close
$ 221.91
$ 227.73
Change
+5.82 +2.62%
Day low
Day high
$221.45
$228.15

52 week low
52 week high
$177.05
$276.69

Market cap
$131.53B
Average volume
2.49M
P/E ratio
18.50
Rev. per Employee
$1.04M
EPS
12.31
Dividend
1.76
Div yield
3.09%
Ex dividend date
5/14/21
MarketWatch News on AMGN
-
Moderna Inc. stock falls Friday, underperforms market
- MarketWatch Automation
-
Amgen Acquires a Cancer Drug. Expect More Deals.
- Bill Alpert
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Dow's 150-point climb led by gains in shares of Chevron, UnitedHealth
- MarketWatch Automation
-
Dow's nearly 50-point jump highlighted by gains in shares of Chevron, Coca-Cola
- MarketWatch Automation
-
Amgen affirms 2021 adj. EPS outlook $16.00-$17.00; FactSet consensus $16.80
- Tomi Kilgore
-
Amgen to pay $38 in cash for each Five Prime share, a 79% premium
- Tomi Kilgore
-
Amgen to buy Five Prime Therapeutics in a deal valued at $1.9 bln
- Tomi Kilgore
-
Moderna Inc. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Moderna Inc. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Moderna Inc. stock rises Monday, still underperforms market
- MarketWatch Automation
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Moderna Inc. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Moderna Inc. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Home Depot, Apple Inc. share losses lead Dow's 100-point drop
- MarketWatch Automation
-
Moderna Inc. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Moderna Inc. stock underperforms Monday when compared to competitors
- MarketWatch Automation
-
Moderna Inc. stock outperforms market on strong trading day
- MarketWatch Automation
-
Moderna Inc. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Analysts’ Latest Recommendations on Mylan
- MarketRealist.com
-
Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
- MarketRealist.com
Other News on AMGN
-
William Blair Sticks to Its Hold Rating for Amgen (AMGN)
- SmarterAnalyst
-
Amgen: 10-12% Upside Going Into March
- Seeking Alpha
-
ETFs to Tap Amgen's Drive for Cancer Deal
- Zacks.com
-
Amgen (AMGN) Gets a Hold Rating from Raymond James
- SmarterAnalyst
-
Amgen: One Of The Few Bargains In This Market
- Seeking Alpha
-
Amgen to acquire Five Prime Therapeutics for $1.9B
- Seeking Alpha
-
High Yield Dividend Stock Watchlist For March 2021
- Seeking Alpha
-
Your Dogs Of The Dow For March
- Seeking Alpha
-
Amgen (AMGN) Receives a Buy from Oppenheimer
- SmarterAnalyst
-
DGI For The DIY: 2020 Dividend Portfolio Review
- Seeking Alpha
-
Dividend Champion And Contender Highlights: Week Of February 28
- Seeking Alpha
- Loading more headlines...
Earnings Announcement
Press Releases on AMGN
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com